Glaucoma

BMJ (Online)

Volumn 346, Issue 7912, 2013, Pages

  King, Anthony ^a   Azuara Blanco, Augusto ^b   Tuulonen, Anja ^c  

^a NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

^b QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^c TAMPERE UNIVERSITY HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGLAUCOMA AGENT; EYE DROPS; PROSTAGLANDIN;

BLINDNESS; CATARACT EXTRACTION; CLINICAL FEATURE; CLOSED ANGLE GLAUCOMA; COST EFFECTIVENESS ANALYSIS; DISEASE CLASSIFICATION; DISEASE COURSE; DRUG SAFETY; EYE PHOTOGRAPHY; GENETIC ASSOCIATION; GLAUCOMA; HUMAN; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; IRIDECTOMY; LASER SURGERY; LOW LEVEL LASER THERAPY; OPEN ANGLE GLAUCOMA; PATIENT COMPLIANCE; PRIORITY JOURNAL; REVIEW; SCREENING TEST; TRABECULECTOMY; TRABECULOPLASTY; UNSPECIFIED SIDE EFFECT; VISION TEST; VISUAL ACUITY;

BLINDNESS; COST-BENEFIT ANALYSIS; DISEASE PROGRESSION; FEMALE; GLAUCOMA; HUMANS; INTRAOCULAR PRESSURE; MALE; MEDICATION ADHERENCE; PROSTAGLANDINS A, SYNTHETIC; RISK FACTORS; TRABECULECTOMY;

EID: 84879218285     PISSN: None     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.f3518     Document Type: Review

References (38)

1. WHO. Global data on visual impairments 2010. www.who.int/blindness/ GLOBALDATAFINALforweb.pdf.
2. Murray CJ, Vos T, Lozano R, Naghavi M, Flaxman AD, Michaud C, et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012;380:2197-223.
3. Spry PG, Spencer IC, Sparrow JM, Peters TJ, Brookes ST, Gray S, et al. The Bristol Shared Care Glaucoma Study: reliability of community optometric and hospital eye service test measures. Br J Ophthalmol 1999;83:707-12. (Pubitemid 29261662)
4. Coleman AL, Miglior S. Risk factors for glaucoma onset and progression. Surv Ophthalmol 2008;53(suppl 1):S3-10.
5. Burr JM, Mowatt G, Hernandez R, Siddiqui MA, Cook J, Lourenco T, et al. The clinical effectiveness and cost-effectiveness of screening for open angle glaucoma: a systematic review and economic evaluation. Health Technol Assess 2007;11:iii-iv, ix-x, 1-190.
6. Bunce C, Xing W, Wormald R. Causes of blind and partial sight certifications in England and Wales: April 2007-March 2008. Eye (Lond) 2010;24:1692-9.
7. Tuulonen A, Airaksinen PJ, Erola E, Forsman E, Friberg K, Kaila M, et al. The Finnish evidence-based guideline for open-angle glaucoma. Acta Ophthalmol Scand 2003;81:3-18. (Pubitemid 36621899)
8. Rudnicka AR, Mt-Isa S, Owen CG, Cook DG, Ashby D. Variations in primary open-angle glaucoma prevalence by age, gender, and race: a Bayesian meta-analysis. Invest Ophthalmol Vis Sci 2006;47:4254-61. (Pubitemid 46579346)
9. Ng WS, Agarwal PK, Sidiki S, McKay L, Townend J, Azuara-Blanco A. The effect of socio-economic deprivation on severity of glaucoma at presentation. Br J Ophthalmol 2010;94:85-7.
10. Fraser S, Bunce C, Wormald R. Risk factors for late presentation in chronic glaucoma. Invest Ophthalmol Vis Sci 1999;40:2251-7. (Pubitemid 29418379)
11. Sukumar S, Spencer F, Fenerty C, Harper R, Henson D. The influence of socioeconomic and clinical factors upon the presenting visual field status of patients with glaucoma. Eye (Lond) 2009;23:1038-44.
12. Fingert JH. Primary open-angle glaucoma genes. Eye (Lond) 2011;25:587-95.
13. National Institute for Health and Clinical Excellence Glaucoma. Diagnosis and management of chronic open angle glaucoma and ocular hypertension. CG85. 2009. www.nice.org.uk/nicemedia/live/12145/43839/43839.pdf.
14. Kass MA, Heuer DK, Higginbotham EJ, Johnson CA, Keltner JL, Miller JP, et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol 2002;120:701-13; discussion 829-30. (Pubitemid 34620348)
15. Miglior S, Zeyen T, Pfeiffer N, Cunha-Vaz J, Torri V, Adamsons I. Results of the European Glaucoma Prevention Study. Ophthalmology 2005;112:366-75. (Pubitemid 40312486)
16. Advanced Glaucoma Intervention Study (AGIS): 7. The relationship between control of intraocular pressure and visual field deterioration. AGIS Investigators. Am J Ophthalmol 2000;130:429-40.
17. Ernest PJ, Schouten JS, Beckers HJ, Hendrikse F, Prins MH, Webers CA. An evidence-based review of prognostic factors for glaucomatous visual field progression. Ophthalmology 2012; published online 1 Dec.
18. Hattenhauer MG, Johnson DH, Ing HH, Herman DC, Hodge DO, Yawn BP, et al. The probability of blindness from open-angle glaucoma. Ophthalmology 1998;105:2099-104. (Pubitemid 30211780)
19. Wittenborn JS, Rein DB. Cost-effectiveness of glaucoma interventions in Barbados and Ghana. Optom Vis Sci 2011;88:155-63.
20. Vaahtoranta-Lehtonen H, Tuulonen A, Aronen P, Sintonen H, Suoranta L, Kovanen N, et al. Cost effectiveness and cost utility of an organized screening programme for glaucoma. Acta Ophthalmol Scand 2007;85:508-18. (Pubitemid 47163112)
21. Burr JM, Botello-Pinzon P, Takwoingi Y, Hernandez R, Vazquez-Montes M, Elders A, et al. Surveillance for ocular hypertension: an evidence synthesis and economic evaluation. Health Technol Assess 2012;16:1-271, iii-iv.
22. Heijl A, Leske MC, Bengtsson B, Hyman L, Hussein M. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol 2002;120:1268-79. (Pubitemid 36105431)
23. Tuulonen A. Cost-effectiveness of screening for open angle glaucoma in developed countries. Indian J Ophthalmol 2011;59(suppl):S24-30.
24. Maier PC, Funk J, Schwarzer G, Antes G, Falck-Ytter YT. Treatment of ocular hypertension and open angle glaucoma: meta-analysis of randomised controlled trials. BMJ 2005;331:134.
25. Heijl A, Alm A, Bengtsson B, Bergstrom A, Calissendorff B, Lindblom B, et al. The glaucoma guidelines of the Swedish Ophthalmological Society. Acta Ophthalmol Suppl (Oxf) 2012;251:1-40.
26. Burr J, Azuara-Blanco A, Avenell A, Tuulonen A. Medical versus surgical interventions for open angle glaucoma. Cochrane Database Syst Rev 2012;9:CD004399.
27. Kass MA, Gordon M, Meltzer DW. Can ophthalmologists correctly identify patients defaulting from pilocarpine therapy? Am J Ophthalmol 1986;101:524-30. (Pubitemid 16114196)
28. Olthoff CM, Schouten JS, van de Borne BW, Webers CA. Noncompliance with ocular hypotensive treatment in patients with glaucoma or ocular hypertension an evidence-based review. Ophthalmology 2005;112:953-61. (Pubitemid 40797446)
29. Gray TA, Orton LC, Henson D, Harper R, Waterman H. Interventions for improving adherence to ocular hypotensive therapy. Cochrane Database Syst Rev 2009;2:CD006132.
30. Rolim de Moura C, Paranhos A Jr, Wormald R. Laser trabeculoplasty for open angle glaucoma. Cochrane Database Syst Rev 2007;4:CD003919.
31. Wong MH, Husain R, Ang BC, Gazzard G, Foster PJ, Htoon HM, et al. The Singapore 5-Fluorouracil Trial: intraocular pressure outcomes at 8 years. Ophthalmology 2013; published online 1 Mar.
32. Gedde SJ, Singh K, Schiffman JC, Feuer WJ. The Tube Versus Trabeculectomy Study: interpretation of results and application to clinical practice. Curr Opin Ophthalmol 2012;23:118-26.
33. Haymes SA, LeBlanc RP, Nicolela MT, Chiasson LA, Chauhan BC. Glaucoma and on-road driving performance. Invest Ophthalmol Vis Sci 2008;49:3035-41.
34. Szlyk JP, Mahler CL, Seiple W, Edward DP, Wilensky JT. Driving performance of glaucoma patients correlates with peripheral visual field loss. J Glaucoma 2005;14:145-50. (Pubitemid 40389184)
35. Haymes SA, Leblanc RP, Nicolela MT, Chiasson LA, Chauhan BC. Risk of falls and motor vehicle collisions in glaucoma. Invest Ophthalmol Vis Sci 2007;48:1149-55. (Pubitemid 351261409)
36. Tanabe S, Yuki K, Ozeki N, Shiba D, Abe T, Kouyama K, et al. The association between primary open-angle glaucoma and motor vehicle collisions. Invest Ophthalmol Vis Sci 2011;52:4177-81.
37. Bhargava JS, Patel B, Foss AJ, Avery AJ, King AJ. Views of glaucoma patients on aspects of their treatment: an assessment of patient preference by conjoint analysis. Invest Ophthalmol Vis Sci 2006;47:2885-8. (Pubitemid 351639762)
38. Sena DF, Lindsley K. Neuroprotection for treatment of glaucoma in adults. Cochrane Database Syst Rev 2013;2:CD006539.